Erasca Inc. Common Stock vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.27 (market cap $2.45B). The key difference: Erasca Inc. Common Stock is far larger — about 2.1× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and Erasca Inc. Common Stock is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| ERAS | UUUU | |
|---|---|---|
Market Cap | $5.17B | $2.45B |
Volume | 5,313,379 | 7,967,898 |
Sector | Health | Energy |
52-Week High | $22.47 | $27.72 |
52-Week Low | $2.20 | $8.34 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $2.19B |
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →